vs
Side-by-side financial comparison of Inogen Inc (INGN) and MEDIFAST INC (MED). Click either name above to swap in a different company.
MEDIFAST INC is the larger business by last-quarter revenue ($75.1M vs $68.6M, roughly 1.1× Inogen Inc). On growth, Inogen Inc posted the faster year-over-year revenue change (3.4% vs -36.9%). Inogen Inc produced more free cash flow last quarter ($-1.9M vs $-6.6M). Over the past eight quarters, Inogen Inc's revenue compounded faster (4.2% CAGR vs -34.4%).
Inogen Inc is a medical technology firm specializing in the development, production and distribution of portable oxygen concentrators and associated respiratory care products. It caters primarily to patients with chronic respiratory conditions needing long-term oxygen therapy across North America, Europe and other global markets, focusing on home care and ambulatory patient segments to enhance users' quality of life.
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
INGN vs MED — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $68.6M | $75.1M |
| Net Profit | — | — |
| Gross Margin | 51.4% | 69.4% |
| Operating Margin | -13.6% | -10.4% |
| Net Margin | — | — |
| Revenue YoY | 3.4% | -36.9% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.26 | $-1.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $68.6M | $75.1M | ||
| Q3 25 | $79.1M | $89.4M | ||
| Q2 25 | $79.2M | $105.6M | ||
| Q1 25 | $68.5M | $115.7M | ||
| Q4 24 | $66.3M | $119.0M | ||
| Q3 24 | $74.9M | $140.2M | ||
| Q2 24 | $74.4M | $168.6M | ||
| Q1 24 | $63.1M | $174.7M |
| Q4 25 | — | — | ||
| Q3 25 | $-5.3M | $-2.3M | ||
| Q2 25 | $-4.2M | $2.5M | ||
| Q1 25 | $-6.2M | $-772.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-6.0M | $1.1M | ||
| Q2 24 | $-5.6M | $-8.2M | ||
| Q1 24 | $-14.6M | $8.3M |
| Q4 25 | 51.4% | 69.4% | ||
| Q3 25 | 52.2% | 69.5% | ||
| Q2 25 | 52.2% | 72.6% | ||
| Q1 25 | 53.1% | 72.8% | ||
| Q4 24 | 54.7% | 74.1% | ||
| Q3 24 | 55.2% | 75.4% | ||
| Q2 24 | 57.4% | 73.2% | ||
| Q1 24 | 54.5% | 72.8% |
| Q4 25 | -13.6% | -10.4% | ||
| Q3 25 | -9.0% | -4.6% | ||
| Q2 25 | -7.7% | -1.0% | ||
| Q1 25 | -11.2% | -1.1% | ||
| Q4 24 | -17.2% | 0.6% | ||
| Q3 24 | -10.4% | 1.5% | ||
| Q2 24 | -9.5% | -4.7% | ||
| Q1 24 | -25.8% | 4.5% |
| Q4 25 | — | — | ||
| Q3 25 | -6.7% | -2.5% | ||
| Q2 25 | -5.2% | 2.3% | ||
| Q1 25 | -9.0% | -0.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -8.0% | 0.8% | ||
| Q2 24 | -7.5% | -4.8% | ||
| Q1 24 | -23.1% | 4.8% |
| Q4 25 | $-0.26 | $-1.64 | ||
| Q3 25 | $-0.20 | $-0.21 | ||
| Q2 25 | $-0.15 | $0.22 | ||
| Q1 25 | $-0.25 | $-0.07 | ||
| Q4 24 | $-0.41 | $0.08 | ||
| Q3 24 | $-0.25 | $0.10 | ||
| Q2 24 | $-0.24 | $-0.75 | ||
| Q1 24 | $-0.62 | $0.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.7M | $167.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $192.2M | $198.9M |
| Total Assets | $298.6M | $248.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $103.7M | $167.3M | ||
| Q3 25 | $106.5M | $173.5M | ||
| Q2 25 | $103.7M | $162.7M | ||
| Q1 25 | $118.9M | $164.6M | ||
| Q4 24 | $113.8M | $162.3M | ||
| Q3 24 | $105.7M | $170.0M | ||
| Q2 24 | $97.9M | $163.5M | ||
| Q1 24 | $107.4M | $156.4M |
| Q4 25 | $192.2M | $198.9M | ||
| Q3 25 | $197.2M | $214.7M | ||
| Q2 25 | $199.5M | $216.0M | ||
| Q1 25 | $198.0M | $211.0M | ||
| Q4 24 | $173.9M | $210.1M | ||
| Q3 24 | $185.4M | $207.3M | ||
| Q2 24 | $187.6M | $205.3M | ||
| Q1 24 | $191.9M | $211.0M |
| Q4 25 | $298.6M | $248.0M | ||
| Q3 25 | $307.0M | $268.2M | ||
| Q2 25 | $312.0M | $269.3M | ||
| Q1 25 | $308.4M | $280.0M | ||
| Q4 24 | $296.2M | $284.2M | ||
| Q3 24 | $306.2M | $291.2M | ||
| Q2 24 | $308.9M | $293.5M | ||
| Q1 24 | $315.6M | $302.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-943.0K | $-5.3M |
| Free Cash FlowOCF − Capex | $-1.9M | $-6.6M |
| FCF MarginFCF / Revenue | -2.8% | -8.8% |
| Capex IntensityCapex / Revenue | 1.4% | 1.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.7M | $1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-943.0K | $-5.3M | ||
| Q3 25 | $2.2M | $12.1M | ||
| Q2 25 | $4.3M | $-3.4M | ||
| Q1 25 | $-16.8M | $3.4M | ||
| Q4 24 | $-3.0M | $-4.9M | ||
| Q3 24 | $7.0M | $9.1M | ||
| Q2 24 | $6.7M | $13.1M | ||
| Q1 24 | $-4.7M | $7.3M |
| Q4 25 | $-1.9M | $-6.6M | ||
| Q3 25 | $1.6M | $10.8M | ||
| Q2 25 | $3.7M | $-4.8M | ||
| Q1 25 | $-17.1M | $1.9M | ||
| Q4 24 | $-3.3M | $-7.2M | ||
| Q3 24 | $5.3M | $7.7M | ||
| Q2 24 | $6.6M | $11.1M | ||
| Q1 24 | $-6.1M | $5.4M |
| Q4 25 | -2.8% | -8.8% | ||
| Q3 25 | 2.0% | 12.0% | ||
| Q2 25 | 4.6% | -4.5% | ||
| Q1 25 | -24.9% | 1.6% | ||
| Q4 24 | -5.0% | -6.1% | ||
| Q3 24 | 7.1% | 5.5% | ||
| Q2 24 | 8.9% | 6.6% | ||
| Q1 24 | -9.6% | 3.1% |
| Q4 25 | 1.4% | 1.8% | ||
| Q3 25 | 0.7% | 1.5% | ||
| Q2 25 | 0.9% | 1.3% | ||
| Q1 25 | 0.4% | 1.3% | ||
| Q4 24 | 0.5% | 1.9% | ||
| Q3 24 | 2.2% | 1.0% | ||
| Q2 24 | 0.1% | 1.1% | ||
| Q1 24 | 2.1% | 1.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.36× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.04× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INGN
| Other | $36.1M | 53% |
| Non Us | $32.5M | 47% |
MED
Segment breakdown not available.
